Skip to main content
Neuro-Oncology logoLink to Neuro-Oncology
. 2019 Nov 11;21(Suppl 6):vi198–vi199. doi: 10.1093/neuonc/noz175.827

QOLP-07. A PILOT STUDY TO ASSESS THE INTEGRATION OF A UNIQUE PROQOL TOOL AND EARLY PALLIATIVE CARE INTERVENTION IN THE CARE OF HIGH GRADE GLIOMA PATIENTS AND THEIR CAREGIVERS

Akanksha Sharma 1, Eric Wolfe 2, Celina Barrera 1, Samantha Williamson 1, Hannah Farfour 1, Maciej Mrugala 3, Mark Edwin 1, Jeff Sloan 2, Alyx Porter 1
PMCID: PMC6847351

Abstract

BACKGROUND

Early involvement of palliative care (PC) in patients with metastatic cancer has been associated with improved quality of life (QOL). Patients with high grade glioma (pwHGG) and their caregivers have unique needs such that similar results are anticipated in this population but cannot be extrapolated. Recognizing that pwHGG often require a caregiver early in the course of disease, this patient population also experiences significant personal and caregiver distress that has been given limited attention and resources. AIM: To assess the feasibility of implementation of a novel patient reported outcomes (PRO) quality of life (QOL) tool administered by smart device in routine office visit (OV) and early integration of palliative care (PC) for pwHGG and their caregivers to improve QOL for both. DESIGN: Prospective, single-center cluster-randomized pilot conducted for 6 months during completion of adjuvant therapy for newly diagnosed high grade glioma. After informed consent was obtained, 15 pwHGG and their caregivers were randomized to: routine OV with basic QOL survey; OV with PROQOL; or PC consultation, in addition to OV with PROQOL.

RESULTS

Two elderly patients with declining performance status transitioned to hospice after initial visit, and one moved out of state prior to adjuvant visits. Thus far 5/15 patients/caregivers have successfully completed the pilot with the 6 remaining participants due to complete in November 2019.

DISCUSSION

The PROQOL appears to be easily integrated into OV without significant patient, caregiver, or provider burden. Providers confirmed utility in prioritizing symptoms and concerns. Thus far, it appears that patients (and caregivers) appeared to benefit from the PROQOL and PC support as evidenced by longitudinal improvement in QOL scores over the control group.

CONCLUSIONS

A unique PROQOL tool and early PC can be easily integrated into practice, and may improve the QOL of pwHGG and their caregivers.


Articles from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Oxford University Press

RESOURCES